Patient P-01684
Synthetic patientNBL-101 · Day 117 · 45–54 · F · baseline S13Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
20%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S13
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Inflammatory activity-9
- GI instability-6
- Nutritional resilience+4
- Treatment adherence-2
- Toxicity+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion23.5/100
improving · -6.9 vs previous 14 d
Toxicity
Blood25.5/100
worsening · +5.3 vs previous 14 d
Sleep quality
Wearable32.2/100
improving · +6.1 vs previous 14 d
Energy level
Daily log5.4/10
stable · +0.1 vs previous 14 d
Stress level
Daily log5.4/10
stable · -0.1 vs previous 14 d
Steps
Wearable9,576
stable · +36 vs previous 14 d
Adherence
Companion88.5 %
stable · -0.3 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 72 from the failing basin, 20 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Daily walks resumedperturbation · steering +3.3
Main detractors to watch
- Enterobacteriaceae elevatedhidden · steering -7.4
- IL6 high-expression varianthidden · steering -7.3
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Simple carbohydrates+0.8no signal · 32%
- Alcohol-0.4no signal · 15%
- Dietary fat load+0.3no signal · 15%
- Spicy / capsaicin-0.3no signal · 15%
- Histamine load+0.1no signal · 15%
- Insoluble fibre+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Autonomic recovery ↓20
- WearableShort sleep window
- Mucosal barrier integrity ↓10
- WearableSleep 5.9 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.2 · butyrate capacity 54/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 48 ms
- Sleep
- 6.0 h
- Steps
- 8,243
- Resting HR
- 67 bpm
Daily log: GI score 24, nutritional resilience 62, adherence 89.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.